CRISM Therapeutics Corporation
CRTX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £1 | £2 | £17 | £32 |
| - Cash | £1 | £3 | £3 | £5 |
| + Debt | £0 | £1 | £0 | £0 |
| Enterprise Value | -£0 | -£1 | £14 | £27 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -56.4% | – | – | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 84% | 28.9% | – | – |
| EBITDA | -£1 | -£2 | -£2 | -£1 |
| % Margin | -2,264% | -3,937.9% | – | – |
| Net Income | -£1 | -£10 | -£2 | -£2 |
| % Margin | -2,428% | -16,816.6% | – | – |
| EPS Diluted | -0.1 | -0.27 | -0.28 | -0.18 |
| % Growth | 63% | 3.6% | -55.6% | – |
| Operating Cash Flow | -£1 | -£3 | -£3 | -£1 |
| Capital Expenditures | -£0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£1 | -£3 | -£3 | -£1 |